BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21569650)

  • 1. [The EML4-ALK fusion gene in NSCLC and the clinical progress].
    Wu D; Yu H
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):435-40. PubMed ID: 21569650
    [No Abstract]   [Full Text] [Related]  

  • 2. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
    Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
    Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
    Okamoto I; Nakagawa K
    Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
    Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
    Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 8. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new target in non-small cell lung cancer: EML4-ALK fusion gene].
    Wang H; Yuan J; Ma Z
    Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):538-42. PubMed ID: 21645460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anaplastic lymphoma kinase with the echinoderm microtubule-associated protein-like 4, fusion gene and non-small cell lung cancer].
    Xia N; Hu CP
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):125-7. PubMed ID: 22455969
    [No Abstract]   [Full Text] [Related]  

  • 12. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
    Thunnissen E; Bubendorf L; Dietel M; Elmberger G; Kerr K; Lopez-Rios F; Moch H; Olszewski W; Pauwels P; Penault-Llorca F; Rossi G
    Virchows Arch; 2012 Sep; 461(3):245-57. PubMed ID: 22825000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
    Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.
    Voena C; Varesio LM; Zhang L; Menotti M; Poggio T; Panizza E; Wang Q; Minero VG; Fagoonee S; Compagno M; Altruda F; Monti S; Chiarle R
    Oncotarget; 2016 May; 7(22):33316-30. PubMed ID: 27119231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
    Tiseo M; Gelsomino F; Boggiani D; Bortesi B; Bartolotti M; Bozzetti C; Sammarelli G; Thai E; Ardizzoni A
    Lung Cancer; 2011 Feb; 71(2):241-3. PubMed ID: 21168933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.